Search

Displaying results 2281 - 2290 of 10000 in total
  1. Drug

    Panthenol

    go.drugbank.com/drugs/DB11204
    Approved

    Furthermore, it acts as a topical protectant, moisturizer, and has demonstrated anti-inflammatory properties [A32377].

    Mixtures: VITEKSIR 100 ML SURUP, MULTIMIX PEDIATRIK SURUP, 100 MLProducts: bdr Re-set 4D age-repair code
  2. Drug

    Sacubitril

    go.drugbank.com/drugs/DB09292
    ApprovedInvestigational

    It was approved by the FDA after being given the status of priority review for on July 7, 2015.

    Mixtures: ENTRESTO 100 MG, ENTRESTO 100 MG
  3. Drug

    N-acetyltyrosine

    go.drugbank.com/drugs/DB11102
    ApprovedInvestigational

    It is typically administered as a source of nutritional support where oral nutrition is inadequate or cannot be tolerated.

    Mixtures: Aminosyn II 7% M In 10% Dextrose(dual Chamber), AMINOPLASMAL-10% E INFUSION
  4. Drug

    Levorphanol

    go.drugbank.com/drugs/DB00854
    Approved

    It is nearly as effective orally as by injection.

  5. Drug

    Casdozokitug

    go.drugbank.com/drugs/DB17513
    Investigational

    Synonyms: ), CDR-IMGT [8.8.19] (26-33.51-58.97-115)) (1-126), immunoglobulin G1-kappa, anti-[IL27 (interleukin 27,IL27p28, IL27A)], Homo sapiens monoclonal antibody,gamma1 heavy chain Homo sapiens (1-456) [VH (Homo sapiens IGHV3-21*01 (95.9%) -(IGHD) -IGHJ5*02 (100%
  6. Drug

    Tozorakimab

    go.drugbank.com/drugs/DB16473
    Investigational

    Tozorakimab (MEDI3506), developed by AstraZeneca, was investigated in multiple clinical trials to evaluate its safety, tolerability, efficacy, and pharmacokinetics across various conditions. These trials include NCT03096795 (completed; h...

    Synonyms: (121)) CDR-IMGT [8.8.19] (26-33.51-58.97-1, Immunoglobulin G1-lambda2, anti-[Homo sapiens IL33 (interleukin 33, DVS27, NF-HEV, IL1F11)], monoclonal antibody; gamma1 heavy chain (1-456) [VH (Homo sapiens IGHV3-23*01 (93.9%) -(IGHD) -IGHJ4*01 (85.7%) L123>M
  7. Drug

    Bimekizumab

    go.drugbank.com/drugs/DB12917
    ApprovedInvestigational

    Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. … [A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment

  8. Drug

    Bazedoxifene

    go.drugbank.com/drugs/DB06401
    ApprovedInvestigational

    It is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy.

    Mixtures: DUAVİVE 0.45 MG/20 MG DEĞİŞTİRİLMİŞ SALIMLI TABLET, 30 TABLET, DUAVIVE 20 mg/0.45 mg modified - release tablets
  9. Drug

    Navepegritide

    go.drugbank.com/drugs/DB17824
    ApprovedInvestigational

    Achondroplasia, the most prevalent skeletal dysplasia, is caused by a gain-of-function variant in the fibroblast growth factor receptor 3 (FGFR3), which leads to overactive downstream signaling that inhibits endochondral ossification, re...

  10. Drug

    mRNA-1010

    go.drugbank.com/drugs/DB22484
    Approved

    [L64058] The FDA approved mFLUSIVA on August 5, 2026 for active immunization against influenza in adults 50 years of age and older, making it the first mRNA-based influenza vaccine approved in the United … [L64058,L64059,L64060] Full approval applies to adults 50 through 64 years, while the indication for adults 65 years and older was granted accelerated approval based on immune responses, with clinical